AnaMar AB is a Swedish-based drug discovery company focused on developing orally bioavailable, peripherally acting 5-HT2B receptor antagonists to prevent pathological fibrotic processes. The company is involved in discovery and early phases of drug development, from idea stage to clinical trials, including invention and optimization of new drug candidates, evaluation of preclinical efficacy and safety, and confirmatory early clinical studies in patients with fibrotic disease.

AnaMar AB

AnaMar AB is developing a first-in-class, anti-fibrotic medicine to prevent, slow and heal scarring caused by fibrosis through its patented suite of serotonin (5-HT2B) receptor antagonists. 

Our selective, oral 5-HT2B receptor antagonist, AM1476, has broad therapeutic potential across fibrotic conditions, which affect millions of patients but have limited, if any, treatment options, including systemic fibrotic disorders and organ-specific fibrotic disorders such as interstitial lung diseases. AM1476 performed successfully in in vitro and in vivo models of fibrosis, as well as demonstrating favourable safety and pharmacokinetic profiles in Phase I clinical studies. It offers a unique dual-action approach to treat skin and lung manifestations of systemic sclerosis.

By targeting peripheral 5-HT2B receptors our antagonists will halt key signaling pathways associated with fibrosis. This specifically reduces 5-HT-induced myofibroblast and macrophage activity and TGF-β production, minimizing side effects and interactions with other medicines. 

We are combining our innovative therapeutic platform with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, using our heritage in diagnostics to ensuring the best outcomes for those with fibrosis. 

We are delighted to announce we have received Orphan Drug Designation (ODD) from the FDA and EMA for the use of AM1476 in the #autoimmune disease systemic #sclerosis (SSc). This is a major milestone on our path to phase II clinical trials. 

AM1476 is our first-in-class, peripheral-acting serotonin receptor antagonist being developed to prevent, heal, and slow, organ scarring caused by #fibrosis in #skin and #lung diseases. 

🔗 Find out more: https://lnkd.in/eDGRGttz

#clinicaltrials #health #drugdiscovery #biotech #pharma #orphandrugs #drugdevelopment #FDA #fdaapproval #innovation #lifesciences #systemicsclerosis #EMA

AnaMar is attending ERS International Congress 
Christina Wenglén Sam Lindgren
Hope to see you! 

#ERSCongress #fibrosis

Each year, on 29 June, the scleroderma community comes together to celebrate World Scleroderma Day. It is a day to recognize the bravery of those who live with #scleroderma  (also known as systemic sclerosis), and demand equal treatment and care for patients, both across Europe and worldwide.

The AnaMar Team show our support for World Scleroderma Day and for the organizations that support people with systemic sclerosis, while continuing develop a new treatment that will help patients to find the light to bloom.
#fibrosis #lifesciences 

ANAM

COM:ANAMAR

AnaMar AB

locale

market

industry

website

crunchbase

linkedin

peer of

Metrics